Market closed
BridgeBio Pharma/$BBIO
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Ticker
$BBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
728
Website
BridgeBio Pharma Metrics
BasicAdvanced
$6.6B
-
-$2.88
1.07
-
Price and volume
Market cap
$6.6B
Beta
1.07
52-week high
$39.47
52-week low
$21.62
Average daily volume
3.3M
Financial strength
Current ratio
4.668
Quick ratio
5.069
Long term debt to equity
-118.727
Total debt to equity
-118.727
Interest coverage (TTM)
-5.81%
Management effectiveness
Return on assets (TTM)
-49.24%
Return on equity (TTM)
38.81%
Valuation
Price to revenue (TTM)
29.031
Price to book
-4.48
Price to tangible book (TTM)
-4.41
Price to free cash flow (TTM)
-12.163
Growth
Revenue change (TTM)
2,285.27%
Earnings per share change (TTM)
-27.13%
3-year revenue growth (CAGR)
47.10%
3-year earnings per share growth (CAGR)
-9.60%
What the Analysts think about BridgeBio Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
BridgeBio Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BridgeBio Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BridgeBio Pharma News
AllArticlesVideos
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
GlobeNewsWire·3 days ago
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Benzinga·1 week ago
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BridgeBio Pharma stock?
BridgeBio Pharma (BBIO) has a market cap of $6.6B as of April 03, 2025.
What is the P/E ratio for BridgeBio Pharma stock?
The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of April 03, 2025.
Does BridgeBio Pharma stock pay dividends?
No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of April 03, 2025.
When is the next BridgeBio Pharma dividend payment date?
BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for BridgeBio Pharma?
BridgeBio Pharma (BBIO) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.